Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GLTO logo GLTO
Upturn stock ratingUpturn stock rating
GLTO logo

Galecto Inc (GLTO)

Upturn stock ratingUpturn stock rating
$3.42
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: GLTO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $6

1 Year Target Price $6

Analysts Price Target For last 52 week
$6Target price
Low$2.01
Current$3.42
high$16.07

Analysis of Past Performance

Type Stock
Historic Profit -79.4%
Avg. Invested days 44
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 4.52M USD
Price to earnings Ratio -
1Y Target Price 6
Price to earnings Ratio -
1Y Target Price 6
Volume (30-day avg) 2
Beta 1.32
52 Weeks Range 2.01 - 16.07
Updated Date 06/30/2025
52 Weeks Range 2.01 - 16.07
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -15.4

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -35.94%
Return on Equity (TTM) -88.35%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -5983533
Price to Sales(TTM) -
Enterprise Value -5983533
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.46
Shares Outstanding 1322360
Shares Floating 1215565
Shares Outstanding 1322360
Shares Floating 1215565
Percent Insiders 3.59
Percent Institutions 13.05

Analyst Ratings

Rating 2
Target Price 6
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Galecto Inc

stock logo

Company Overview

overview logo History and Background

Galecto, Inc. is a biotechnology company focused on developing novel treatments for fibrosis and cancer. Founded in 2011, it has progressed through preclinical and clinical stages, primarily concentrating on galectin inhibitors.

business area logo Core Business Areas

  • Fibrosis Drug Development: Develops galectin-3 inhibitors to treat fibrotic diseases, including liver, lung, and kidney fibrosis.
  • Cancer Immunotherapy: Explores the use of galectin inhibitors in combination with cancer immunotherapy to enhance treatment efficacy.

leadership logo Leadership and Structure

The leadership team includes Hans Schambye (CEO) and other executives with backgrounds in pharmaceutical development and commercialization. The organizational structure is typical of a biotechnology company, with research, clinical development, and commercial operations departments.

Top Products and Market Share

overview logo Key Offerings

  • GB0139: An inhaled formulation of a galectin-3 inhibitor being developed for idiopathic pulmonary fibrosis (IPF). Market share is currently 0% as the product is in clinical trials. Competitors in the IPF market include Boehringer Ingelheim (Ofev) and Roche (Esbriet).
  • GB1211: An oral galectin-3 inhibitor being developed for liver fibrosis and NASH. Market share is currently 0% as the product is in clinical trials. Competitors in the NASH market include Madrigal Pharmaceuticals (Resmetirom) and Viking Therapeutics (VK2809).

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry is characterized by high R&D costs, long development timelines, and regulatory hurdles. The fibrosis and cancer markets are large and growing, driven by aging populations and increasing prevalence of chronic diseases.

Positioning

Galecto is positioned as a specialist in galectin biology, focusing on developing galectin inhibitors for fibrotic diseases and cancer. Their competitive advantage lies in their proprietary galectin inhibitor platform.

Total Addressable Market (TAM)

The TAM for fibrosis and NASH therapeutics is estimated to be over $20 billion annually. Galecto is positioned to capture a share of this market if its clinical trials are successful and products are approved.

Upturn SWOT Analysis

Strengths

  • Proprietary galectin inhibitor platform
  • Experienced leadership team
  • Focus on unmet medical needs
  • Clinical-stage product pipeline

Weaknesses

  • Limited financial resources
  • Reliance on clinical trial success
  • Competition from established pharmaceutical companies
  • High R&D costs

Opportunities

  • Positive clinical trial results
  • Partnerships with larger pharmaceutical companies
  • Expansion into new indications
  • Increased awareness of galectin biology

Threats

  • Clinical trial failures
  • Regulatory setbacks
  • Competition from new therapies
  • Patent expirations

Competitors and Market Share

competitor logo Key Competitors

  • BI
  • RHHBY
  • MRVL
  • VKTX

Competitive Landscape

Galecto faces competition from established pharmaceutical companies with greater resources and broader product portfolios. Its competitive advantage lies in its focus on galectin biology and its proprietary galectin inhibitor platform. However, it is in direct competition with companies developing drugs for the same or similar indications.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is primarily reflected in the advancement of its clinical pipeline and expansion of its research programs.

Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals for its lead product candidates. Analyst estimates will vary based on their assessments of the company's pipeline and market potential.

Recent Initiatives: Recent initiatives include advancing GB0139 and GB1211 through clinical trials, exploring new indications for its galectin inhibitors, and seeking potential partnerships.

Summary

Galecto is a clinical-stage biopharmaceutical company focused on galectin inhibitors, primarily for fibrosis and cancer. While it holds promise with its innovative approach, its success is heavily dependent on positive clinical trial outcomes and regulatory approvals. The company faces intense competition and relies on securing funding to sustain its operations. Success in clinical trials and commercialization are key milestones to watch for.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Company Website
  • Analyst Reports
  • Industry Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investment decisions should be made based on individual financial circumstances and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Galecto Inc

Exchange NASDAQ
Headquaters -
IPO Launch date 2020-10-29
Co-Founder, President, CEO & Director Dr. Hans T. Schambye M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 5
Full time employees 5

Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.